Wedbush Raises Price Target on Idenix Pharmaceuticals (IDIX) Following Pipeline Update
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Price: $24.50 --0%
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 22 | New: 45
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 22 | New: 45
Join SI Premium – FREE
Wedbush is reiterating its Outperform rating on shares of Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and is raising its price target from $15 to $16 despite missing its Q4 expectations.
The company provided an update on its pipeline, which the firms notes was pretty encouraging. An analyst at Wedbush comments, "We continue to view IDIX as a likely take-out candidate based on the company’s core competence in nucleoside-based therapies, as well as its promising albeit early NS5A data."
For Q1, the firm is estimating EPS of ($0.15) on $1.8 million in revenues. Wedbush forecasts EPS will be ($0.53) for FY12 as revenues come in at $7.4 million.
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $12.29 yesterday.
The company provided an update on its pipeline, which the firms notes was pretty encouraging. An analyst at Wedbush comments, "We continue to view IDIX as a likely take-out candidate based on the company’s core competence in nucleoside-based therapies, as well as its promising albeit early NS5A data."
For Q1, the firm is estimating EPS of ($0.15) on $1.8 million in revenues. Wedbush forecasts EPS will be ($0.53) for FY12 as revenues come in at $7.4 million.
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $12.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phoenix Education Partners (PXED) PT Lowered to $40 at Morgan Stanley
- AbraSilver Resource Corp (ABRA:CN) PT Raised to Cdn$21 at Scotiabank
- MDA Space Ltd (MDA:CN) (MDA) PT Lowered to Cdn$67 at Scotiabank
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
